HUTCHMED (China) (HMDCF) Income from Non-Controlling Interests (2015 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Income from Non-Controlling Interests came in at -$27.6 million in Q4 2021, down 993.73% quarter-over-quarter from $3.1 million in Q3 2021.
Analysis
HUTCHMED (China) (HMDCF) Income from Non-Controlling Interests (2015 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Income from Non-Controlling Interests for 6 consecutive years, with -$27.6 million the latest figure, recorded in Q4 2021.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to -$27.6 million in Q4 2021; TTM through Dec 2021 was -$27.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$823000.0, down 86.62% from the prior year.
- Income from Non-Controlling Interests was -$27.6 million for Q4 2021 at HUTCHMED (China), down from $3.1 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $3.9 million in Q2 2018 and troughed at -$27.6 million in Q4 2021.
- A 4-year average of -$2.0 million and a median of -$644500.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests surged 158.79% in 2019 and tumbled 191.78% in 2020, its largest moves.
- Over 4 years, Income from Non-Controlling Interests stood at $788000.0 in 2018, then tumbled by 172.84% to -$574000.0 in 2019, then decreased by 27.7% to -$733000.0 in 2020, then slumped by 3671.21% to -$27.6 million in 2021.
- The last three Income from Non-Controlling Interests figures came in at -$27.6 million (Q4 2021), $3.1 million (Q3 2021), and -$1.8 million (Q2 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | -100.77 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -27.64 Mn |
| Sep 28, 2021 | 3.09 Mn |
| Jun 30, 2021 | -1.77 Mn |
| Mar 31, 2021 | -1.29 Mn |
| Jun 30, 2020 | -733,000.00 |
| Mar 31, 2020 | -715,000.00 |
| Dec 31, 2019 | -574,000.00 |
| Sep 30, 2019 | 143,000.00 |
| Jun 30, 2019 | -2.69 Mn |
| Mar 31, 2019 | 779,000.00 |
| Dec 31, 2018 | 788,000.00 |
| Sep 30, 2018 | 165,000.00 |
| Jun 30, 2018 | 3.89 Mn |
| Mar 31, 2018 | -1.33 Mn |
| Jun 30, 2016 | -37,000.00 |
| Jun 30, 2015 | 67,000.00 |